Home/ Stocks/ BIVI

BioVie, Inc. Common Stock

BIVI XNAS

$1.47 -0.04 (-2.60%) ▼ 15-min delayed

Open

$1.54

High

$1.55

Low

$1.42

Volume

111.2K

Market Cap

$11.08M

About BioVie, Inc. Common Stock

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-6,069,475	$-0.77
Q1 2026	$0	$-5,087,557	$-0.98
FY 2025	$0	$-17,542,120	$-12.12
Q3 2025	$0	$-2,788,418	$-0.15

Related Market News

No specific coverage for BIVI yet. Check out our latest market news or earnings calendar.

Get BIVI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioVie, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.